Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 79M | 70M | 60M | 54M | 46M |
| Gross Profit | 46M | 43M | 48M | 43M | 36M |
| Operating Income | -71M | 6M | 9M | 15M | 11M |
| EBITDA | 15M | 12M | 13M | 19M | 15M |
| Net Income | -65M | 10M | 10M | 12M | 10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$18.24
-0.05% today
Window Change
+9.16%
Window
May 28, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 28, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Simulations Plus, Inc. (SLP) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $18.24 and up 9.2% across the available one-year price window (May 28, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +13.1%, EPS growth of -744.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.1%, EPS -744.0%, free cash flow +36.5% with operating margin -83.5% and ROIC -47.4%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLP Max Drawdown
-10.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$46.5M
-13.8% YoY
FY Net Income
$9.8M
-21.6% YoY
Free Cash Flow
$14.6M
+5.0% YoY
Revenue Growth
+13.1%
EPS Growth
-744.0%
Gross Margin
62.0%
Net Margin
-78.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 79M | 70M | 60M | 54M | 46M |
| Gross Profit | 46M | 43M | 48M | 43M | 36M |
| Operating Income | -71M | 6M | 9M | 15M | 11M |
| EBITDA | 15M | 12M | 13M | 19M | 15M |
| Net Income | -65M | 10M | 10M | 12M | 10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31M | 10M | 58M | 52M | 37M |
| Total Assets | 132M | 208M | 193M | 191M | 182M |
| Total Liabilities | 7M | 25M | 23M | 12M | 16M |
| Shareholder Equity | 125M | 182M | 170M | 178M | 166M |
| Total Debt | 616K | 1M | 1M | 1M | 1M |
| Net Debt | -30M | -9M | -56M | -50M | -36M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
19M
+7.3% YoY
Capital Expenditures
5M
-15.3% YoY
Free Cash Flow
15M
+5.0% YoY
Key ratios
Gross Margin
62.0%
Operating Margin
-83.5%
Net Margin
-78.0%
ROE
-49.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.